Theranostics is an emerging paradigm that combines imaging and therapy in order to
personalize patient treatment. In nuclear medicine, this is achieved by using …

Radiopharmaceutical therapy (RPT) involves the use of radionuclides that are either
conjugated to tumor-targeting agents (eg, nanoscale constructs, antibodies, peptides, and …

Theranostics refers to the pairing of diagnostic biomarkers with therapeutic agents that share
a specific target in diseased cells or tissues. Nuclear medicine, particularly with regard to …

In 2005, the term theragnostics (theranostics) was introduced for describing the use of
imaging for therapy planning in radiation oncology. In nuclear medicine, this expression …

Molecular Imaging and Radiotherapy: Theranostics for Personalized Patient Management -
PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI …

A search in PubMed revealed that 72 radionuclides have been considered for molecular or
functional targeted radionuclide therapy. As radionuclide therapies increase in number and …

In radiopharmaceutical therapy (RPT), a radionuclide is systemically or locally delivered with
the goal of targeting and delivering radiation to cancer cells while minimizing radiation …

Radiopharmaceutical therapy (RPT) has grown rapidly over the last decade for treatment of
numerous cancer types. Dosimetric guidance, as with other radiotherapy modalities, has …

This article reintroduces and reinforces our proposed paradigm that involves specific
individual “dual-purpose” radionuclides or radionuclide pairs with emissions suitable for …

For treatment of systemic malignancies, when external radiation therapy is not applicable,
radionuclide therapy can be an alternative. In this form of therapy, radionuclides are …